Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
05 January 2022 - 08:17AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”)
today announced that members of the management team will
participate in two upcoming virtual investor conferences.
- H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand
presentation available Monday, January 10, 2022, beginning at 7:00
a.m. EST thru Thursday, January 13, 2022 (access here)
- J.P Morgan 40th Annual Healthcare Conference. Presentation to
be hosted on Thursday, January 13, 2022 at 9:45 am EST (access
here)
Interested parties can also register and access these
presentations under "News/Events” through the “Investors” section
of the Aurinia corporate website at www.auriniapharma.com.
ABOUT AURINIA
Aurinia is a fully integrated biopharmaceutical company focused
on delivering therapies to treat targeted patient populations that
are impacted by serious diseases with a high unmet medical need. In
January 2021, the Company introduced the first FDA-approved oral
therapy indicated for the treatment of adult patients with active
lupus nephritis (LN). Aurinia’s head office is in Victoria, British
Columbia; its U.S. commercial hub is in Rockville, Maryland; and
the Company focuses development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005906/en/
Investor and Corporate: Dana Lynch, Corporate
Communications & IR dlynch@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2023 to Mar 2024